Adopting technological advances in upstream and downstream processes is vital to the gene therapy space, says Kai Lipinski, CSO at ReciBioPharm. Here he explores emerging technology trends and discusses how they can help to overcome key challenges facing gene therapy manufacturers.
The number of approved gene therapies for the treatment of monogenetic disorders and diseases has increased in recent years, reflecting the field’s rapid advances and the development of revolutionary new technologies and techniques. The increasing adoption of technologies promoting safety, efficacy and reduced production costs has been a persistent trend that will continue to benefit the industry and help to treat a broader patient population.
This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.
Key learning points:
Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
Learn about ITM’s implementation journey and considerations when evaluating the technology
Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).
Don’t miss your chance to learn from experts in the industry –Register for FREE
Can’t attend live? No worries – register to receive the recording post-event.
Capabilities in suspension cell lines and proprietary cell lines are becoming increasingly important to competitiveness within the gene therapy industry
By streamlining upstream and downstream processing (USP and DSP) with the incorporation of new technologies, drug developers can improve safety and efficacy while lowering production costs, potentially reducing drug prices and thereby helping to promote patient access. Production cost is currently a fundamental concern for many gene therapy developers, particularly given that some treatments cost millions of dollars per single dose (eg, $3.5 million for Hemgenix [AAV5-hFIX-Padua]).1 As revolutionary upstream and downstream technologies become a reality, biopharma companies will need to determine how best to integrate them into their current systems.
Innovating the upstream
The design and optimisation of USP is key to creating a successful therapeutic. Innovations in biotechnology, such as genetic engineering, enable the development of optimised microbial strains and production processes, leading to increased yields, reduced production costs and enhanced scalability. This enhances the commercial viability of USP. There are numerous avenues where these advances are converging to benefit the gene therapy industry. As a result, we can expect to see growing numbers of gene therapy developers and manufacturers adopting new techniques and technologies into their upstream processes.
Suspension and proprietary cell lines
The demand for large batches of gene therapy products is driving the use of suspension cell lines to facilitate scaling capacities. This demand is coupled with a movement to produce stably transfected proprietary cell lines that can shorten timelines and produce high-quality products. Having proprietary cell lines in house can also speed up USP by reducing the need to outsource and the time required to grow the cells before use. Proprietary cell lines also allow companies to attain IP and build brand recognition.2 Capabilities in suspension cell lines and proprietary cell lines are becoming increasingly important to competitiveness within the gene therapy industry.
Upstream single-use systems and scalability
Improvements to manufacturing systems fully based on single-use systems (SUS) have enabled scalability up to 6,000L, if needed.3 Industry research and development has also given manufacturers better media and supplements that facilitate high productivity even in the absence of foetal bovine serum for suspension-based gene therapy vector manufacture.4
Novel inducible systems for enhanced control
Inducible systems allow external cues to control the precise onset of gene expression. Advanced inducible systems to better regulate the expression of certain genes will improve the generation of packaging and producer cell clones, giving companies more control over gene expression for improved safety as well as efficiency.
Dynamism in downstream processes
As with upstream processes, there are also many technologies set to elevate downstream processes (DSP) in gene therapy development and manufacturing. These advances in downstream technology aim to reduce levels of process-related contaminants for the safety, quality and stability of the final product.
Single-use systems
One notable trend in DSP is the adoption of SUS technologies.
By introducing advanced SUS technologies into depth filtration, cross-flow filtration, chromatography and final sterile filtration steps, gene therapy developers can decrease the risk of contamination and the amount of validation needed compared with permanent fittings. SUS also enables rapid scaling of production, providing a quick response to changes in market demand and faster turnaround times as cleaning or changeover is not required. As compared with stainless steel alternatives, SUS offers reduced cleaning requirements – from decreased water and energy consumption to reduced waste – helping to meet sustainability needs.5
Advanced analytical technologies
Another trend in this area is the adoption of increasingly sophisticated analytical technologies.
Achieving cost optimisation requires identifying opportunities for process simplification, improving productivity and optimising resources
Gene therapy products are very complex and manufactured with a cellular host substrate, which makes analytical characterisation far more challenging. Fortunately, researchers and industry have made big steps forward in analytical instrumentation and therefore characterisation of gene therapy viruses. New and improved analytical developments range from digital polymerase chain reaction (PCR), bio-layer interferometry, flow virometry, nano-tracking analysis, flow-induced dispersion analysis, analytical ultracentrifugation and charge detection mass photometry. In part, this progress in analytical testing has been driven by increasing demands from regulatory agencies to show particular safety and potency profiles for therapeutics entering clinical investigation.
Potential challenges to consider when manufacturing gene therapies
Although the advancement of gene therapies is undoubtedly a time of excitement in healthcare, there are also several challenges to consider when planning and executing gene therapy manufacturing. These challenges predominantly surround scalability, stability, regulatory compliance and access to patients.
Viral vector production scalability
Innovations in USP have improved the production of viral vectors at large scales through the development of transient transfection systems and stable producer lines. However, challenges may arise in optimising and scaling up these systems. Scaling up transient transfection can be challenging due to limitations in the efficiency and consistency of transfection across large volumes.6 High transfection efficiency becomes more difficult as the scale increases. Ensuring consistent vector quality is essential and all regulatory requirements related to safety and potency should be considered.
Cost optimisation
Although advances in gene therapy also extend to technology that has reduced production costs, these therapies remain expensive due to the complexity of manufacturing processes and the need for specialised facilities and equipment. These can include the development of high‑yield cell lines, improved transfection techniques and optimised bioreactor designs, all of which are advantageous when looking to enhance vector productivity and yield. Achieving cost optimisation requires identifying opportunities for process simplification, improving productivity and optimising resources. Ensuring scalability of these manufacturing processes is essential for cost optimisation.7
Regulatory compliance in an evolving space
Gene therapies are subject to rigorous regulatory requirements to ensure patient safety and product efficacy. These can be complex as the regulatory guidelines on gene therapies are constantly evolving. Moving forward, manufacturers should be familiar with and adhere to good manufacturing practice (GMP), demonstrating robust assurance systems throughout the manufacturing process of such therapeutic products.8
Supply chain management
Ensuring a secure and reliable supply chain is crucial to meeting the increased demand for gene therapies. Manufacturing gene therapies relies on a complex supply chain of raw materials, critical reagents and specialised components.9 As the therapeutic trends align with gene therapy, manufacturers will need to identify potential vulnerabilities within the supply chain, establish contingency plans and collaborate closely with suppliers to mitigate risks.
Patient access and affordability
Despite the advancements in technology and process optimisation, ensuring patient access to gene therapies at an affordable cost remains a significant challenge.10
We can expect continuous development, improvement and adaptations of regulatory guidelines as the science of gene therapies advances quickly
Manufacturers must work alongside payers, providers and policymakers to develop finance options and establish equitable access programmes to make gene therapies affordable and therefore accessible to a broader patient population.
Each manufacturing process and subsequent gene therapy product will have unique considerations and requirements. As trends change, at times rapidly, these considerations should be re-evaluated and addressed to ensure gene therapy production processes remain seamless.
A persistent trend to heed in future
Gene therapy developers and manufacturers must be aware of the technological developments occurring in USP and DSP and, if necessary, adapt accordingly. Together with their manufacturing partners, gene therapy producers must continue to make efforts to reduce the cost of goods to ensure the commercial viability of therapies and deliver potentially life-changing treatments to patients. Further, we can expect continuous development, improvement and adaptations of regulatory guidelines as the science of gene therapies advances quickly, alongside evolving market access agreements.
References
Naddaf M. $3.5-million hemophilia gene therapy is world’s most expensive drug [Internet]. Scientific American; 2022 [cited 2023 Jun]. Available from: https://www.scientificamerican.com/article/3-5-million-hemophilia-gene-therapy-is-worlds-most-expensive-drug/
Nielsen J, Tillegreen CB, Petranovic D. Innovation trends in Industrial Biotechnology. Trends in Biotechnology. 2022;40(10):1160–72.
Bhatkhande S. Single-use bioprocessing technologies enabling more rapid vaccines production [Internet]. 2023 [cited 2023 Jun]. Available from: https://www.americanpharmaceuticalreview.com/Featured-Articles/596309-Single-Use-Bioprocessing-Technologies-Enabling-More-Rapid-Vaccines-Production/
Subbiahanadar Chelladurai K, Selvan Christyraj JD, et al. Alternative to FBS in animal cell culture – an overview and future perspective. Heliyon. 2021;7(8).
Hederman J. Single-use systems: The future of biopharmaceutical processing [Internet]. 2023 [cited 2023 Jun]. Available from: https://www.medicaldesignbriefs.com/component/content/article/mdb/pub/features/articles/40742
Shupe J, Zhang A, Odenwelder DC, Dobrowsky T. Gene therapy: Challenges in cell culture scale-up. Current Opinion in Biotechnology. 2022;75:102721.
Cost reduction in cell and gene therapy 2023: Cost-efficiency coupled with efficacy is key moving forward – researchandmarkets.com [Internet]. 2023 [cited 2023 Jun]. Available from: https://www.businesswire.com/news/home/20230105005524/en/Cost-Reduction-in-Cell-and-Gene-Therapy-2023-Cost-Efficiency-Coupled-With-Efficacy-is-Key-Moving-Forward—ResearchAndMarkets.com
Addressing the unique regulatory challenges of Gene Therapies [Internet]. 2022 [cited 2023 Jun]. Available from: https://www.biopharma-excellence.com/articles/addressing-the-unique-regulatory-challenges-of-gene-therapies/
Digiusto D, Leistler B, Walls T. Overcoming raw material challenges in Cell & Gene Therapy Manufacturing. Cell and Gene Therapy Insights. 2020;6(2):415–26.
UK BioIndustry Association. Ensuring patient access to cell and gene therapies [Internet]. 2021 [cited 2023 Jun]. Available from: https://www.bioindustry.org/resource-listing/ensuring-patient-access-to-cell-and-gene-therapies—the-case-for-an-innovative-payment-model-pdf.html
About the author
Kai Lipinski, PhD joined Vibalogics, now ReciBioPharm, in 2010 as Head of Cell Culture and Virus Production. He was named Head of Process Development in 2013, then promoted to Chief Scientific Officer (CSO) in 2020. At ReciBioPharm, Kai is central to the establishment of virus process development and manufacturing capabilities as well as technical developments. Kai has a wealth of experience in viral vector manufacturing. He served as Principal Scientist at Cobra Biologics, focusing on USP development for virus and mammalian protein expression projects. Prior to that, he worked as Senior & Principal Scientist at ML Laboratories, where he was responsible for the development of targeted adenoviral vectors for cancer gene therapy approaches. Kai has a PhD in Transcriptional Regulation by Adenoviral E1A Proteins and a Post-Doc, also on Transcriptional Regulation, from the University of Duisburg-Essen, Germany.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.